Dr. Philip Lammers, a medical oncologist, is the chief of the Division of Hematology/Oncology at Meharry Medical College and adjunct assistant professor of internal medicine at Vanderbilt University. He has several active research projects on ways to increase minority and underserved population representation in clinical trials. He also studies state-of-the art cancer treatments, including biosimilars. Listen to the podcast to hear Dr. Lammers explain: what a biosimilar drug is, as well as the approval process for biosimilars how we can be sure that biosimilars are as safe as the reference products the advantages and disadvantages of biosimilars when we might see biosimilars on the market to treat breast cancer

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related